Active Biotech

November 03, 2011 03:44 ET

Active Biotech AB Interim Report January - September 2011

LUND, SWEDEN--(Marketwire - Nov 3, 2011) -


* Laquinimod - Phase III BRAVO trial concluded. Teva plans an additional
  clinical study before filing a registration application in the US
* TASQ - enrolment of patients for Phase III trial ongoing
* TASQ -  Phase II trial published in Journal of Clinical Oncology
* ANYARA - Phase III trial proceeding according to plan
* 57-57 - a clinical trial in  being prepared in systemic sclerosis
* ISI - project is proceeding as planned
* RhuDex® - preparations for continued clinical development ongoing
* Net sales  SEK 231.3 M (8.5)
* Operating loss SEK 6.2 M (loss: 149.7)
* Loss after tax SEK 1.3 M (loss: 156,8)
* Loss per share for the period amounted to SEK 0,02 (loss: 2.40)


This report is also available at www.activebiotech.com

Active Biotech AB Interim Report Jan-Sep 2011: http://hugin.info/1002/R/1560312/482696.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE

[HUG#1560312]

Contact Information

  • For further information, please contact:

    Tomas Leanderson
    President and CEO
    Tel +46 (0)46-19 20 95

    Hans Kolam
    CFO
    Tel: +46 (0)46-19 20 44

    Active Biotech AB (Corp. Reg. No. 556223-9227)
    PO Box 724, SE-220 07 Lund
    Tel: +46 (0)46-19 20 00
    Fax: +46 (0) 46-19 11 00